Boehringer Ingelheim partners on DARPin molecules

German family-owned drug major Boehringer Ingelheim’s biopharmaceutical contract manufacturing business and Molecular Partners have entered into a strategic manufacturing collaboration.

Under the terms of the accord, financial terms of which were not revealed, Boehringer Ingelheim will be responsible for the generation of E. coli production strains and the manufacture of tox and clinical stage material for multiple DARPin products supplying Molecular Partners’ proprietary DARPin pipeline.

Simon Sturge, corporate senior vice president Boehringer Ingelheim Biopharmaceuticals, commented: “We are happy to have entered into this collaboration with Molecular Partners as we believe the DARPin platform will play an important role in the development of next generation antibody like proteins. This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects.”